With increased attention to ICH E6(R2) guidance and on achieving higher levels of transparency and speed, many pharmaceutical companies have begun to implement new CRO oversight practices.
This webinar presents the results of a recent study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) that benchmarks CRO oversight practices and their impact and effectiveness.
Ken Getz of Tufts CSDD discusses the summary results of the study and their implications. Specific areas covered include:
- CRO oversight models
- Oversight challenges
- Performance metrics for oversight effectiveness
- Insights into new best practices